COVID-19, Dysfunctional Breathing
Conditions
Keywords
COVID-19, Dysfunctional breathing, Hyperventilation syndrome, Sighs, erratic breathing
Brief summary
Dysfunctional breathing might participate to dyspnoea in long COVID-19. This study investigate the prognosis of patients diagnosed with dysfunctional breathing after SARS-CoV-2 infection in our center.
Detailed description
Dysfunctional breathing (DB) with or without hyperventilation syndrome (HVS) as diagnosed using cardiopulmonary exercise test (CPET) was recently demonstrated as an important physiopathological mechanism of persistent dyspnoea in long COVID patients \[1\]. DB is characterized by specific ventilation pattern on CPET accompanied by respiratory discomfort and/or dyspnea at exercise \[2\]. Most patients with DB will have undergone some sort a specific physiotherapy retraining \[3\]. However the prognostic and the predictors of persistence/resolution of DB after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are unknown. The aim of the study is to determine the prognostic of patients diagnosed with DB after SARS-CoV-2 infection, as well as prognosis factors and predictors of persistence/resolution of DB during a prospective follow up visit.
Interventions
None listed
Sponsors
Hôpital du Valais
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients 14 years or more * diagnosis of DB after SARS-CoV-2 at our long covid clinic using a combined approach of symptoms and CPET analysis in the hospitals of Sion, Martigny or Rennaz * Inclusion between November 2020 and until the end of October 2021
Exclusion criteria
* Refusal to participate * comorbidities preventing the CPET or PFT to be carried out
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Persistence/resolution of dysfunctional breathing at follow-up visit | 6 to 9 monts from diagnosis | defined by persistence/resolution of dyspnea, as compared with patient's baseline (equivalent level of dyspnea as before COVID-19). |
Secondary
| Measure | Time frame |
|---|---|
| Dispersion of VT and BF during the CPET | 6 to 9 monts from diagnosis |
| Change in ETCO2 and PaCO2 | 6 to 9 monts from diagnosis |
| Qualitative changes (increase/decrease/no change of DB pattern of CPET) | 6 to 9 monts from diagnosis |
| Score HADS changes | 6 to 9 monts from diagnosis |
| Change in ventilatory patterns (tidal volume [VT], breathing frequency [BF] at isowork as compared with baseline | 6 to 9 monts from diagnosis |
| Specific symptom scale changes | 6 to 9 monts from diagnosis |
| Specific work capacity changes questions | 6 to 9 monts from diagnosis |
| Post-COVID Functional Status (PCFS) changes | 6 to 9 monts from diagnosis |
| Score SF-36 changes | 6 to 9 monts from diagnosis |
Countries
Switzerland
Contacts
Primary ContactPierre-Olivier v Bridevaux
Backup ContactLéon Genecand
Outcome results
None listed